Health Canada
- Status: approved
Amivantamab and Recombinant Human Hyaluronidase (Amivantamab and Recombinant Human Hyaluronidase) regulatory status in Canada.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. Health Canada has authorised it.
National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.